AsclepiX Therapeutics

Asclepi X Therapeutics

Biotechnology, 185 Hudson St, Baltimore, Maryland, 07311, United States, 1-10 Employees

asclepix.com

  • facebook
  • twitter
  • LinkedIn

Who is ASCLEPIX THERAPEUTICS

FRAUD ALERT: AsclepiX is aware of individuals representing job postings that are not legitimate positions. AsclepiX is NOT hiring at this time. AsclepiX Therapeutics is a clinical-stage b...

Read More

map
  • 185 Hudson St, Baltimore, Maryland, 07311, United States Headquarters: 185 Hudson St, Baltimore, Maryland, 07311, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2836

checked-icon Does something look wrong? Fix it. | View contact records from ASCLEPIX THERAPEUTICS

AsclepiX Therapeutics Org Chart and Mapping

Employees

Steven Altschuler

Therapeutics Managing Director

Aleksander Popel

Founder and Chief Scientific Advisor

Scott Cerulli

Clinical Finance Manager

Amir Shojaei

Chief Scientific Officer, Evp-Clinical Development

Sarah Pettorsson

Director, Business Operations and Administration

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AsclepiX Therapeutics

Answer: AsclepiX Therapeutics's headquarters are located at 185 Hudson St, Baltimore, Maryland, 07311, United States

Answer: AsclepiX Therapeutics's official website is https://asclepix.com

Answer: AsclepiX Therapeutics's revenue is $1 Million to $5 Million

Answer: AsclepiX Therapeutics's SIC: 2836

Answer: AsclepiX Therapeutics has 1-10 employees

Answer: AsclepiX Therapeutics is in Biotechnology

Answer: AsclepiX Therapeutics contact info: Phone number: Website: https://asclepix.com

Answer: FRAUD ALERT: AsclepiX is aware of individuals representing job postings that are not legitimate positions. AsclepiX is NOT hiring at this time. AsclepiX Therapeutics is a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases. Our lead candidate, AXT107, inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access